Scripps Research Study Describes New Tool In The Fight Against Autoimmune Diseases, Blood Cancers

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia…

Go to Source

People who read this also read

• Mental illness gene identified
  Scottish researchers have made a breakthrough as they identified a gene that could help explain the causes of mental illness. The international team of scientists, led by experts at Edinburgh University, discovered the gene ABCA13 that may help create drugs to restore mental health in patients wi...
• Cancer-busting fat found in soy
  A FATTY ingredient in soy may explain its ability to combat bowel cancer, research suggests. Scientists believe soy's cancer-fighting secret is molecules called sphingadie (Source: Scotsman.com News - Health) Go to SourceRelated Sitescancer bowel | Cancer BlogTalking Cancer » Link between remo...
• An ancient light-harvesting protein is critical for the regulation of algal photosynthesis
  Authors: Graham Peers, Thuy B. Truong, Elisabeth Ostendorf, Andreas Busch, Dafna Elrad, Arthur R. Grossman, Michael Hippler & Krishna K. Niyogi Light is necessary for photosynthesis, but its absorption by pigment molecules such as chlorophyll can cause severe oxidative damage and result in cell ...
• ARIAD Receives Orphan Drug Designations For Its Investigational Pan BCR-ABL Inhibitor, AP24534, In Chronic Myeloid Leukemia
  ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for t...
• Sunesis Poised For Phase 3 Trial Of Voreloxin In Acute Myeloid Leukemia After Completing Formal End-of-Phase 2 Meetings With FDA
  Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) related to its lead compound, voreloxin, in acute myeloid leukemia (AML). Sunesis has received feedback and guidance from the FDA in response t...